Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg

Press Release For Immediate Release Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg Mumbai, India and Mahwah, New Jersey, November 22, 2022 – Glenmark Pharmaceuticals Inc., USA (Glenmark) and Glenmark Pharmaceuticals Limited have reached a settlement agreement with Pfizer Inc., PF Prism C.V. , and PF Prism IMB B.V. (Pfizer) for Axitinib Tablets, 1 mg and 5 mg , the generic version of their Inlyta® 1 Tablets, 1 mg and 5 mg. Glenmark had previously announced it received tentative approval by the United States Food & Drug Administration (U.S. FDA) for their generic Axitinib Tablets, 1 mg and 5 mg on November 30, 2020. According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta® Tablets, 1 mg and 5 mg market2 achieved annual sales of approximately $644.5 million*. Glenmark’s current portfolio consists of 177 products authorized for distributio n in the U.S. marketplace and 47 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external developme nt partnerships to supplement and accelerate the growth of its existing pipeline and portfolio. ---End--- About Glenmark Pharmaceuticals Ltd Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation‐driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncolog y. The company has 10 world‐class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off‐ patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com. LinkedIn (Glenmark Pharmaceuticals), Instagram (glenmark_pharma). For further information, please contact: Udaykumar Murthy |Tel: +91 9960377617 | Email: [email protected] References: 1All brand names and trademarks are the property of their respective owners. 2Market includes brand and all available therapeutic equivalents, which may include indications for which Glenmark is not tentatively approved. *IQVIATM National Sales Perspectives: Retail & Non-Retail, September 2022

The release as fetched from its publisher. glenmarkpharma.com ↗